TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03673553

Intervention type: OTHER
Intervention: Multimodal treatment of patients with FM
Description: The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.

Intervention type: OTHER
Intervention: Association of people with fibromyalgia
Description: The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
Study: NCT00126568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT03170531

Intervention type: DIAGNOSTIC_TEST
Intervention: Custom Designed Spine Coil
Description: During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDA approved spine coil
Description: During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
Study: NCT01655576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placental drainage
Description: After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
Study: NCT04538625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 125 MG [Mytesi]
Description: Randomized, Double-blind, Placebo-controlled, two arm trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT01244425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant (FS) VH S/D 500 s-apr
Description: Dosage form: spray application; dosage frequency: single application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Dosage form: surgical gauze swab; dosage frequency: single application
Study: NCT01194180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG: 100 microlitres ~ 2-8 x 105 pfu
Description: BCG vaccination at day C (challenge day) then punch biopsy at day C+14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG: 100 microlitres ~ 2-8 x 105 pfu
Description: BCG vaccination at day C (challenge day) then punch biopsy at day C+14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
Description: MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
Description: MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
Study: NCT02180152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postprandial walks
Description: Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
Study: NCT02204163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutropin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Study: NCT04337125

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological and attachment/parenting assessment
Description: Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological and attachment/parenting assessment
Description: Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment.
Study: NCT00615095

Intervention type: OTHER
Intervention: self-administered questionnaire and blood draw
Description: Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.

Intervention type: OTHER
Intervention: self-administered questionnaire and blood draw
Description: Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.

Intervention type: OTHER
Intervention: health questionnaire, blood draw and skin exam
Description: Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
Study: NCT01922128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MC-1101, Placebo
Description: One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MC-1101, Placebo
Description: One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
Study: NCT01035372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dried plum powder
Description: subjects will have 25% of their diet substituted by dried plum powder
Study: NCT01759667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A standard mixed Meal
Description: All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
Study: NCT00702884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Sunitinib 37.5 mg daily for a 4 week cycle
Study: NCT00692120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: 50,000 IU once monthly for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (vitamin D2)
Description: oral capsule 50,000 IU once monthly for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (vitamin D2)
Description: oral capsule 1600 IU once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: oral capsule 1600 IU once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo capsule once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo capsule once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo capsule once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo capsule once daily for 12 months
Study: NCT03406169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 25 MG Oral Tablet
Description: twice a day dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 400mg twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo twice a day
Study: NCT02326181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory pressure training group
Description: The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mixed training group
Description: The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
Study: NCT02105259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Internet Treatment
Description: Psychodynamic Internet Treatment for patients social anxiety disorder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Waiting list, where participants wait for delayed treatment
Study: NCT00345046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: Four drops daily decreasing to once daily over four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EconoPred Plus
Description: Prednisolone Acetate four times daily decreasing to once daily over four weeks.
Study: NCT04556851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg Q2W
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25 mg Q2W
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Study: NCT03621813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Rehabilitation
Description: This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants are instructed to maintain current activity level and are monitored for changes.
Study: NCT01697306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 2 g
Description: six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine
Description: six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
Study: NCT01897168

Intervention type: DEVICE
Intervention: No intervention
Study: NCT04556851

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Study: NCT04492644

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02203331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Study: NCT03220035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study: NCT00469339

Intervention type: BEHAVIORAL
Intervention: Family Health History
Study: NCT01631617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Description: 800/160 orally every 12 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg orally every 8 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg orally every 8 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg orally every 8 hours for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cephalexin
Description: 500 mg orally every 8 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg orally every 8 hours for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cephalexin
Description: 500 mg orally every 8 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: 6 % dilute bleach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: 6 % dilute bleach

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium hypochlorite
Description: 6 % dilute bleach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: 6 % dilute bleach

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Capsule orally every 8 hours daily for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Capsule orally every 8 hours daily for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sodium hypochlorite
Description: Three times a week for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sodium hypochlorite
Description: Three times a week for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sodium hypochlorite
Description: Three times a week for 14 days
Study: NCT01143454

Intervention type: DEVICE
Intervention: NSR IDE-MRI: Research pulse sequences
Description: NSR IDE-MRI: Research pulse sequences, Device Manufacturer NIH. Research pulse sequences are customized pulse sequences and analysis software developed by NIH scientists.

Intervention type: DEVICE
Intervention: NSR IDE-MRI: Research pulse sequences
Description: NSR IDE-MRI: Research pulse sequences, Device Manufacturer NIH. Research pulse sequences are customized pulse sequences and analysis software developed by NIH scientists.
Study: NCT02203331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Study: NCT04462276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy (TRT)
Description: 30 Gy in 10 fractions
Study: NCT03512405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03930498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin and Gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT 60-66Gy, 1.8-2.0Gy/f/day
Study: NCT03483038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
Study: NCT02203331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron / Leuprolide acetate
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
Study: NCT02242045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet(s) administered orally twice daily
Study: NCT03983382

Intervention type: DIAGNOSTIC_TEST
Intervention: Left Ventricular Ejection Fraction
Description: LVEF assessment at baseline, 6 months, and 12 months
Study: NCT02141399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet, taken daily
Study: NCT02650843

Intervention type: OTHER
Intervention: DAT SPECT imaging
Study: NCT03257865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily for 3 weeks.
Study: NCT00749892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study: NCT01273168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-Endoxifen
Description: Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
Study: NCT04255784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS
Description: Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
Study: NCT00592852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks